• and Brookfield Property Partners L.P. (BPY) in BPY's $14.4 billion acquisition of the approximately 66% of common stock that it did not already own of GGP Inc. (f/k/a General Growth Properties Inc.).
• Brookfield Business Partners in its pending $8 billion sale of Westinghouse Electric Company.
• in its approximately $4.8 billion acquisition of a 61.2% stake in Oaktree Capital Group, LLC.
• in its $2.8 billion acquisition of all of the outstanding common shares not already owned by Brookfield Property Partners L.P. of Rouse Properties, Inc., a REIT that owns and manages regional shopping malls in the United States.

• The Dow Chemical Company in its $130 billion all-stock merger of equals with E. I. du Pont de Nemours and Company.
• in its approximately $40 billion spin-off from DowDuPont Inc. as part of DowDuPont's separation into three independent, publicly traded companies, one each for its agriculture, materials science and specialty products businesses.

• in its approximately $8 billion acquisition of Loxo Oncology, Inc.
• in its $5.4 billion acquisition of the animal health business of Novartis AG, making Lilly's animal health business the second-largest animal health company by global revenue.
• in its $1.1 billion acquisition of Dermira, Inc.
• in its acquisitions of CoLucid Pharmaceuticals, Inc., Avid Radiopharmaceuticals, Inc., Lohmann SE, ChemGen Corp., the world-wide rights to an intranasal glucagon from Locemia, and the North American rights to Erbitux® (cetuximab) (including commercialization and manufacturing responsibilities) from Bristol-Myers Squibb Company; and in the sale of veterinary assets to Virbac SA.

• in its $76 billion acquisition of all of the outstanding equity securities of Kinder Morgan Energy Partners, L.P., Kinder Morgan Management, LLC, and El Paso Pipeline Partners, L.P. — at the time, the largest energy merger since Exxon and Mobil combined in 1999.
• in its $5 billion acquisition of Copano Energy.
• in its $38 billion acquisition of El Paso Corporation, creating one of the largest energy companies in the world and in El Paso’s concurrent $7.15 billion sale of its E&P production business, EP Energy Corporation.
• and Kinder Morgan Canada Limited in their $3.5 billion sale of Trans Mountain Pipelines Inc. and the Trans Mountain Expansion Project to the Government of Canada.

• in the $2.15 billion sale of its convenience store business unit to EG Group.
• in its acquisition of Vitacost.com, Inc.
• in its acquisition via tender offer of Roundy’s, Inc.
• in its strategic partnership with, and investment in, Lucky’s Market.

• in its $17.2 billion sale of MGM Growth Properties LLC to VICI Properties Inc.
• in the formation of a joint venture between MGM Growth Properties LLC and Blackstone Real Estate Income Trust to acquire the Las Vegas real estate assets of the MGM Grand and Mandalay Bay for $4.6 billion and to lease back these assets to subsidiaries of MGM Resorts.
• in its $4.25 billion sale of the Bellagio to a joint venture MGM Resorts formed with Blackstone Real Estate Income Trust and its planned leaseback of the Bellagio.
• in its $2.1 billion acquisition of the 50% stake it did not already own in CityCenter and its $3.9 billion sale and leaseback of the Aria Resort and Vdara Hotel real estate at CityCenter.
• in its formation MGM Growth Properties LLC (MGP), a controlled REIT, and in corporate, real estate and tax aspects of MGP’s $1.05 billion initial public offering.
• in its $1.175 billion sale of the real property of the Borgata Hotel Casino & Spa in Atlantic City, New Jersey to MGM Growth Properties LLC. The sale followed MGM Resorts’ $900 million acquisition of the 50% interest in the Borgata that it did not already own from Boyd Gaming Corporation.
• in its $1.625 billion acquisition of the operations of The Cosmopolitan of Las Vegas.
• in its $1.075 billion sale of the operations of The Mirage Hotel & Casino on the Las Vegas Strip to Hard Rock International.

• in its $25 billion exchange of Merial, its animal health business, for the consumer healthcare business of Boehringer Ingelheim GmbH.
• in its $13 billion sale of nearly all of its 20.6% stake in Regeneron Pharmaceuticals, Inc.
• in its $11.6 billion acquisition of Bioverativ Inc.
• in its $4.8 billion acquisition of Ablynx NV.
• in its $3.7 billion acquisition of Principia Biopharma Inc.
• in its $3.2 billion acquisition of Translate Bio, Inc.
• in its $2.5 billion acquisition of Synthorx, Inc.
• in its $2.35 billion sale of Zentiva to Advent International.
• in its $1.9 billion acquisition of Kadmon Holdings, Inc.
• in its up to $1.45 billion acquisition of Kymab, Ltd.
• in its up to $1.225 billion acquisition of Amunix Pharmaceuticals, Inc.

in its $14.6 billion merger with Discovery Communications, Inc.

in its $4 billion acquisition of all of the oil and natural gas assets, liabilities, businesses and operations of Anadarko Petroleum Corporation in Mozambique and South Africa.

• Willis Towers Watson PLC in its proposed $80 billion combination with Aon PLC.
• Willis Group Holdings plc in its $18 billion merger of equals with Towers Watson & Co.
• Willis Towers Watson PLC in its $1.3 billion acquisition of TRANZACT.